MASS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 36 cases where MASS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Following a +10.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where MASS advanced for three days, in 221 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 107 of 132 cases where MASS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The 10-day RSI Indicator for MASS moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 55 cases where MASS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MASS as a result. In 78 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for MASS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 47 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MASS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MASS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.329) is normal, around the industry mean (4.204). P/E Ratio (-10.747) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (5.988) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. MASS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MASS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVCR declined for three days, in 311 of 351 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 68 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for NVCR turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
The Aroon Indicator for NVCR entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVCR's RSI Indicator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 64 cases where NVCR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
Following a +0.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 205 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. NVCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.550) is normal, around the industry mean (4.204). P/E Ratio (-10.162) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
MASS | NVCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 37 | 63 | |
P/E GROWTH RATING 1..100 | 87 | 24 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MASS's Valuation (21) in the null industry is significantly better than the same rating for NVCR (98) in the Medical Specialties industry. This means that MASS’s stock grew significantly faster than NVCR’s over the last 12 months.
MASS's Profit vs Risk Rating (100) in the null industry is in the same range as NVCR (100) in the Medical Specialties industry. This means that MASS’s stock grew similarly to NVCR’s over the last 12 months.
MASS's SMR Rating (96) in the null industry is in the same range as NVCR (98) in the Medical Specialties industry. This means that MASS’s stock grew similarly to NVCR’s over the last 12 months.
MASS's Price Growth Rating (37) in the null industry is in the same range as NVCR (63) in the Medical Specialties industry. This means that MASS’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (24) in the Medical Specialties industry is somewhat better than the same rating for MASS (87) in the null industry. This means that NVCR’s stock grew somewhat faster than MASS’s over the last 12 months.
| MASS | NVCR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 82% |
| Advances ODDS (%) | 7 days ago 81% | 1 day ago 75% |
| Declines ODDS (%) | 1 day ago 85% | 6 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 79% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MASS’s FA Score shows that 1 FA rating(s) are green while NVCR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MASS’s TA Score shows that 3 TA indicator(s) are bullish while NVCR’s TA Score has 4 bullish TA indicator(s).
MASS (@Medical/Nursing Services) experienced а -12.36% price change this week, while NVCR (@Medical/Nursing Services) price change was -8.26% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.23%. For the same industry, the average monthly price growth was -8.25%, and the average quarterly price growth was -9.51%.
MASS is expected to report earnings on Nov 10, 2026.
NVCR is expected to report earnings on Feb 25, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with ALGN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
|---|---|---|---|---|
| NVCR | 100% | +0.46% | ||
| ALGN - NVCR | 38% Loosely correlated | +2.83% | ||
| AZTA - NVCR | 38% Loosely correlated | -8.99% | ||
| TWST - NVCR | 37% Loosely correlated | -15.54% | ||
| A - NVCR | 35% Loosely correlated | -1.65% | ||
| TFX - NVCR | 35% Loosely correlated | +0.64% | ||
More | ||||